Last reviewed · How we verify
Beta-lactamase inhibitor
At a glance
| Generic name | Beta-lactamase inhibitor |
|---|---|
| Also known as | amoxicillin clavulanate potassium compound (Junerqing) |
| Sponsor | Guangzhou Institute of Respiratory Disease |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Irritability
- Diarrhea
- Anaemia
- Diarrhoea
- Headache
- Decubitus ulcer
- Urinary tract infection
- Vomiting
- Allergic Reaction
- Alanine aminotransferase increased
- Hydrothorax
- Infusion Site Phlebitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Beta-lactamase inhibitor CI brief — competitive landscape report
- Beta-lactamase inhibitor updates RSS · CI watch RSS
- Guangzhou Institute of Respiratory Disease portfolio CI